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Background. Medullary thyroid cancer (MTC) is a rare neuroendocrine-derived malignancy. It is represented by sporadic and
familiar forms, and both can have RET oncogene mutations. Numerous markers can be used to deﬁne MTC; however, none is
generally approved for predicting the outcome of sporadic MTC. Aim. The aim of this work was to analyze PTTG1/securin and
Aurora kinase A expressions in MTC patients, both at the gene and protein levels, and to deﬁne their prognostic role in MTC
assessing their association with lab and clinical parameters. Patients and Methods. Seventy-one sporadic MTC human samples
were analyzed for RET mutations and by qPCR for PTTG1 and AURKA (Aurora kinase A) expression. Ki-67 levels and western
blot reactivity for PTTG1 and Aurora kinase A were also determined in a selected cohort of patients. Results. RET somatic
mutations were found in 48% of the patients (34/71). PTTG1 expression was statistically diﬀerent among the groups with or
without regional lymph node metastasis (p < 0 0001) and advanced stage disease (p < 0 01). PTTG1 and AURKA expressions
were statistically higher than those of controls (p = 0 01 and p < 0 002, respectively). PTTG1 expression and Ki-67 levels were
statistically diﬀerent among the groups with remitted or persistent disease (p < 0 05 and p < 0 01, respectively). We found a
signiﬁcant correlation between the expressions of AURKA and PTTG1 (p < 0 0002, r = 0 5298) and between the expressions of
PTTG1 and Ki-67 (p = 0 01). Ki-67 levels were statistically diﬀerent among the groups with or without metastatic lymph nodes
(p = 0 01) or distant metastases (p = 0 003). Conclusion. The presence of an altered expression of PTTG1 and AURKA is a
negative prognostic factor associated with a more aggressive course of disease, such as an advanced stage or disease persistence.
It emerges as a cell cycle process mediated by the 2 factors, in addition to the RET pathway, which can be altered in MTC patients.
1. Background
Medullary thyroid cancer (MTC) is rare neoplasia that
comprises 5-10% of all thyroid tumors [1]. It is character-
ized by the ability to produce calcitonin, a hormone that
regulates the metabolism of calcium and phosphorus.
The majority of MTC cases comprise sporadic cases (75%)
with unilateral masses that frequently metastasize to the
lymph nodes, whereas the hereditary forms (25%) have a
genetic basis and may appear as a bilateral or multifocal mass
[2]. RET (REarranged during Transfection) is an important
protooncogene implicated in MTC tumorigenesis. It is
mutated in about 50% of the sporadic cases of MTC, and
hereditary and sporadic cases show speciﬁc mutations which
are correlated with phenotype and prognosis [3]. The only
potentially curative treatment is surgical resection, though
MTC tends to spread at the locoregional area or metastasize
at a distance. In these cases, a surgical approach is not always
possible and in advanced and progressive MTC cabozantinib
and vandetanib can be used [4]. Furthermore, multiple
markers show a beneﬁcial value for the diagnosis and prog-
nosis of MTC. Calcitonin and CEA (CarcinoEmbryonic
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Antigen) are the most signiﬁcant biochemical markers, in
addition to Ca 19.9 (gastrointestinal cancer marker carbohy-
drate antigen 19.9), while plasma catecholamines, chromo-
granin A, and urinary markers of catecholamine are the
other important ones. Notably, RET alteration and Ki-67
value can deﬁne patient risk stratiﬁcation in sporadic
MTC [5]. Even if numerous molecular markers have been
proposed, no generally accepted indicators can predict the
outcome of MTC.
PTTG1 (Pituitary Tumor-Transforming 1) encodes for a
homolog of yeast securin proteins strictly involved in cell
cycle regulation, because it is fundamental in hindering
separins from promoting sister chromatid separation [6]. It
is therefore named human securin, and its involvement in
cell transformation and tumorigenesis has been demon-
strated [7]. Moreover, it has been found overexpressed in
numerous tumors, including endocrine ones, such as pitui-
tary, breast, and ovarian carcinomas. Also, PTTG1 revealed
a pathogenic role in papillary and medullary thyroid cancers,
being overexpressed during the metaphase-anaphase tran-
sition [8–10]. Also, AURKA (Aurora kinase A), a gene that
encodes for a serine/threonine kinase needed for G2/M
transition, mitosis, and cytokinesis, has been found overex-
pressed in thyroid cancers and numerous cancer types
[11–14]. It must be noted that AURKA overexpression or
mutation can lead to chromosomal instability, centrosome
ampliﬁcation, and malignant transformation, as a result of
cell cycle process deregulation [15].
Given these premises on PTTG1 and AURKA involve-
ment in thyroid tumorigenesis, we decided to explore their
association and their prognostic signiﬁcance in a large cohort
of sporadic medullary thyroid cancer samples.
2. Patients and Methods
2.1. Patients and Biological Specimens. MTC tissues were
obtained surgically from 71 patients; 10 thyroid normal
(TN) samples were also obtained. All patients underwent
total thyroidectomy with the dissection of the regional
lymph nodes. The etiology of each thyroid mass, clinical
diagnoses, malignancy, and staging were established as previ-
ously described [5]. Patients were assumed to have spo-
radic MTC, as no germline mutation was found, no other
endocrine neoplasia was identiﬁed, and family history was
negative. All studies were performed in accordance to the
guidelines of the Declaration of Helsinki. All patients
(including those providing normal samples) gave written
informed consent to the collection and use of thyroid tissue
for research purposes, and the study was approved by the
Local Ethics Committee (Azienda Ospedaliera di Padova,
code number 12667). After surgery, samples were snap fro-
zen and stored at -80°C.
2.2. RET Analysis. DNA was extracted from blood or tissues
using the QIAmp DNA Mini Kit (Qiagen, Germany) as per
the manufacturer’s instruction. DNA was PCR ampliﬁed
and RET (NM_020975.4) exons 5, 8, 10, 11, 13, 14, 15, and
16 were assessed by direct sequencing following previously
published procedures [16].
2.3. Real-Time PCR (qPCR). Total RNA was extracted from
tissues using the TRIzol reagent lysis buﬀer (Invitrogen,
Carlsbad, CA) from fresh snap-frozen samples according to
the manufacturer’s protocol. Real-time PCR (qPCR) was per-
formed in an ABI PRISM 7900HT Sequence Detector
(Applied Biosystems, Milan, Italy) using the relative quantiﬁ-
cation method (2−ΔΔCt method) as previously described [17].
Primer sequences for PTTG1 and AURKA were derived from
previous works [18, 19]. Data were analyzed with the
Sequence Detection Software rel. 2.4 (Applied Biosystems),
adopting an automatically set baseline and a ﬂuorescence
threshold adjusted to measure quantiﬁcation cycle (Ct)
values. Validation experiments performed using the standard
curve method with ﬁve serial dilutions of genomic DNA
from control subjects showed identical ampliﬁcation eﬃcien-
cies (100%±10%) calculated according to the formula E =
101/−slope − 1 for all assays. Using the 2−ΔΔCt method, the
data were presented as the fold change in gene expression
normalized by a reference gene and relative to a calibrator
sample. As the reference gene in this study, we used β-actin,
one of the most commonly used housekeeping genes. A pool
of cDNA derived from mixed normal human thyroid tissues
was used as the calibrator source in our study.
2.4. Ki-67 Immunostaining. Immunohistochemical analysis
was performed on 54 paraﬃn-embedded tissue samples
ﬁxed in formalin with 5mm thick sections, using a stan-
dardized avidin-biotin complex method in an automatic sys-
tem (BenchMark XT; Ventana, Tucson, AZ, USA). The
anti-Ki-67 antibody (Rabbit Monoclonal, clone 30-9, Roche)
was used. For Ki-67 staining, nuclei were considered positive
when a reaction was present as a brown depot (and also when
positivity was conﬁned to the nucleoli). Nuclei were negative
when no immunostaining was perceived.
A 5mm2 area of the tissue was analyzed for every patient,
equal to 3 random 10x ﬁelds of view (FOV). A video-
analytical method (the Image-Pro Plus 7 analysis program)
was used to record the number of positive nuclei in the
FOV. The ﬁnal result was reported as the number of positive
nuclei per 1mm2 of the neoplastic area.
2.5. Stromal Desmoplasia Evaluation. The presence of a des-
moplastic stromal reaction within MTC tissue samples was
determined by 2 authors (GP and FG) on 3μm thick sections
from each paraﬃn-embedded neoplastic tissue sample,
stained with ematossilin and eosin. A tumor was considered
positive for desmoplasia whenever a collagen-rich stroma as
deﬁned above was observed, irrespective of the quantity
and extent of this reaction. Tumors with a poor stroma com-
posed only by vessels and sparse reticular ﬁbers were classi-
ﬁed as negative for desmoplasia.
2.6. Western Blot Analysis. Tumor samples were collected
after surgery, frozen immediately in liquid nitrogen, and
stored at −80°C. Proteins were extracted and electroblotted
onto nitrocellulose membranes as already described [20].
Immunoblot analysis was performed on normal and cancer-
ous MTC tissues. Brieﬂy, membranes were incubated over-
night with the following primary antibodies: anti-PTTG1
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(GeneTex, Irvine, USA), anti-Aurora kinase A (Cell Signal-
ing Technology, Danvers, USA), and anti-β-actin (GeneTex,
Irvine, USA). Then, secondary antibodies were added for 1 h
with anti-mouse and anti-rabbit (1 : 800) secondary IRDye.
Membranes were scanned with the Odyssey CLx system
(LI-COR BioSciences, Milan, Italy) equipped with an infra-
red light technology for the detection. Signal intensity was
quantiﬁed with Image Studio™ software (Version 4.0,
LI-COR BioSciences) following the manufacturer’s instruc-
tions. The experiments were performed three times.
2.7. Statistical Analysis. Statistical analysis was performed
using the MedCalc software (version 11.2.1.0) and GraphPad
Prism (version 5). The probability with p < 0 05 was con-
sidered statistically signiﬁcant. The Kolmogorov-Smirnov
test was used to evaluate the normal distribution of each
numeric parameter. The comparison between the continuous
variables in the considered groups was carried out by
means of the t-test for independent samples and the
Mann–Whitney test. The comparison between categorized
variables was performed by the chi-square test or Fisher’s
exact test. Spearman’s correlation analysis was used to deter-
mine the possible linearity relationship between the variables
under examination.
3. Results
3.1. Patient Clinical Data. Of all sporadic cases of MTC, 42
were females and 29 were males. The mean age at diagnosis
was 61 years (range 35-81 years). The median follow-up
was 46 months (range from 6 to 138 months). Tumors were
staged according to the TNM classiﬁcation: 25 were stage I,
16 were stage II, 9 were stage III, and 21 were stage IV
(Table 1). It was observed that 29 out of 71 patients were
biochemically cured after surgery, while 7 patients were
lost during follow-up. In the group with persistent disease
(35 patients), 77% (27/35 patients) did not show metastases
at diagnosis while 14% (5/35) had metastases at the lymph
nodes of the neck. Furthermore, a signiﬁcantly higher preva-
lence was observed in biochemically cured women than in
men (72% vs. 35%, p < 0 01). During the follow-up, 4 patients
died due to disease progression.
3.2. RET Mutations. No patient had germline mutations in
the RET oncogene. Genetic RET analysis demonstrated a
somatic mutation in 48% of patients (34/71) with MTC.
53% of these mutations (18/34) were localized at codon 918
in exon 16 (M918T). 16 mutations were detected in exons
10, 11, and 15. In particular, mutations in exon 10 were
15% (5/34): two in codon 618 (C618S and C618Y), one
in codon 513 (A513G), one in codon 609 (C609S), and
one in codon 611 (C611R). At exon 11, mutations were
23% (8/34): 18% (6/34) of the cases carried a mutation in
codon 634 (C634Y (3), C634W, C634S, and C634R), while
6% (2/34) carried a mutation in codon 630 (C630R). At
exon 15, mutations in RET were 9% (3/34): 2 patients had
the mutation A883F and 1 patient had a 12-base pair dele-
tion starting from codon 898 (p.D898_E901del) (c.2694_
2705del12). Of the 4 patients who died, 2 presented the
M918T somatic mutation, another the C618S mutation,
and the last one the C618Y mutation.
3.3. Genotype-Phenotype Correlation. In patients with a
mutation, the mean age at diagnosis was lower than that in
patients with a wild-type genotype (mean of 58 years, 95%
CI 53-63 years versus mean of 64 years, 95% CI 59-69 years,
respectively). The prevalence of mutated RET was higher in
females than in males, 53% versus 47%, respectively. There
was no statistically signiﬁcant association between the pres-
ence of somatic RET mutation and the size of the tumor or
capsular inﬁltration or the lymph node metastasis at diagno-
sis or distant metastases.
3.4. PTTG1/Securin. The expression of PTTG1 was evaluated
in qPCR in 71 MTC patients. A higher expression of PTTG1
(approximately 2.5-fold) was shown when compared to the
control group (p = 0 01) (Figure 1(a)). Furthermore, it was
observed that if patients were divided into 2 groups, one in
stages I and II and the other in stages III and IV, the 2 groups
showed a statistically diﬀerent PTTG1 expression (p < 0 0001)
(Figure S1A). Similarly, if PTTG1 expression in relation to
the value of T (primitive tumor) was divided into 2 groups
(one group with T1 and T2 and another with T3 and T4),
its expression was statistically diﬀerent in the 2 groups
Table 1: Clinical and histological features and follow-up in patients
with sporadic MTC in relation to stages I-II and stages III-IV.
Tumor stage Stages I-II (n = 41) Stages III-IV (n = 30)
Age at diagnosis 55 (95% CI 49-62) 61 (95% CI 55-67)
Gender (F/M) 30/11 10/20
Tumor category
(cancer staging)
T1 (27) 23 4
T2 (13) 9 4
T3 (27) 9 18
T4 (4) 0 4
Capsular inﬁltration 5 18
Lymph node
metastasis
N- (43) 41 2
N+ (28) 0 28
Distant metastasis
M- (63) 41 22
M+ (8) 0 8
RET mutation
RET- (37) 22 15
RET+ (34) 19 15
Outcome
Free from disease (29) 27 2
Persistent disease (35) 7 28
Survival
Dead 0 4
Live 41 26
CI: conﬁdence interval.
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Figure 1: Gene and protein expression levels in MTC patients. (a) AURKA (Aurora kinase A gene) expression in 71 MTC patients evaluated
by qPCR (TN=normal thyroid). (b) Representative western blot for PTTG1 and AKA (Aurora kinase A) in 6 MTC patients (3: stage I; 4:
stage I; 5: stage III; 6: stage IV; 7: stage II; and 8: stage IV), 2 controls (healthy thyroid, numbers 1 and 2), and 1 patient with papillary
thyroid carcinoma (number 9). (c) PTTG1 expression in 71 MTC patients evaluated by qPCR (TN=normal thyroid). (d) Spearman’s
correlation between PTTG1 and AURKA expression levels for 71 MTC patients evaluated by qPCR. (e) Spearman’s correlation between
Ki-67 and PTTG1 expression levels for 54 MTC patients.
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(p < 0 01) (Figure S1B). In addition, PTTG1 expression was
statistically diﬀerent among the groups with or without
regional lymph node metastasis (p < 0 0001) (Figure S1C).
Also, MTC persistence or remission was evaluated: PTTG1
expression was statistically diﬀerent among the groups
with remitted or persistent disease (p < 0 05) (Figure S1D).
No other signiﬁcant diﬀerence was found analyzing for the
presence or absence of distant metastases, RET mutations,
calcitonin value, and tumor size.
We also evaluated the expression of PTTG1 by western
blot on 6 MTC patients (a small representative number of
patients), 2 controls (healthy thyroid), and 1 patient with
papillary thyroid carcinoma (PTC), used as positive control
(it has been reported to express elevated quantities of
PTTG1 [21]). PTTG1 expression is present in a variable
manner in all MTC patients, while healthy controls showed
lower reactivity. PTC patients exhibited large amounts of
PTTG1 (Figure 1(b)).
3.5. AURKA/Aurora Kinase A. AURKA expression was
evaluated by qPCR in 71 MTC patients. A higher expression
of AURKA (approximately 1.7-fold) was shown if compared
to the control group (p < 0 002) (Figure 1(c)). We also
observed that the expression levels of PTTG1 and AURKA
diﬀer signiﬁcantly (p< 0.01), whereas we found a signiﬁcant
correlation between the expression of AURKA and PTTG1
(p < 0 0002) (Figure 1(d)). Several clinical and laboratory
parameters were additionally evaluated to discover potential
statistical associations, but we did not identify any further
signiﬁcant data.
In addition, we evaluated the expression of Aurora kinase
A (AKA) by western blot on 6 MTC patients (a small repre-
sentative number of patients), 2 controls (healthy thyroid),
and 1 patient with papillary thyroid carcinoma (PTC), used
as positive control (it has been reported to express elevated
quantities of AKA [22]). AKA expression is present in a
variable manner in all patients with MTC, while healthy con-
trols showed lower reactivity. PTC patients exhibited large
amounts of AKA (Figure 1(b)).
3.6. Ki-67 Immunohistochemistry. A statistically diﬀerent
expression emerged in patients with or without metastatic
lymph nodes (median 40, 95% CI 19-81/mm2 versus 13,
95% CI 7-22/mm2, p = 0 01) or in those with or without
distant metastases (median 40, 95% CI 19-81/mm2 to 13,
95% CI 7-22/mm2, p = 0 003). Also, MTC persistence or
remission was evaluated: Ki-67 expression levels were statis-
tically diﬀerent among the groups with remitted or persistent
disease (p < 0 01). In addition, we found a signiﬁcant correla-
tion between the expression levels of Ki-67 and PTTG1
(p = 0 01).
Furthermore, by dividing the expression of Ki-67 into 2
levels (> or <50 cells/mm2), the relationship between the dis-
ease stage and expression levels could be calculated (p < 0 05)
(Figure 1(e)). It is notable that the presence of high Ki-67
reactivity is associated with a more advanced stage. Nuclear
Ki-67 expression levels were not signiﬁcantly associated with
gender, age, or cancer size.
3.7. Stromal Desmoplasia. Desmoplasia was deﬁned as the
presence of a newly formed ﬁbrotic collagenous stroma
surrounding the invasive neoplastic cells [23]. We evalu-
ated our cohort of samples for the presence or absence
of any stromal desmoplasia reaction. We showed a statis-
tically signiﬁcant association between lymph node metastasis
(p < 0 001) and stromal desmoplasia (Figure S2A). Similarly,
we observed a statistically signiﬁcant association between
PTTG1 expression (p = 0 01) and stromal desmoplasia
(Figure S2B).
4. Discussion
This work analyzed 71 consecutive sporadic cases of MTC,
one of the most representative casuistry from a unique Italian
centre. We showed that 48% of patients carried a mutation in
the oncogene RET, with the M918T alteration the more fre-
quent, as already reported in the literature [3]. Other rare
mutations have also been identiﬁed and some patients
did not show any mutations in the RET oncogene, underlin-
ing as other genetic RET regions can potentially be involved
(intronic regions, regulatory regions, etc.) or as other
unknown genes may play a speciﬁc role in the pathogenesis
of MTC. It should be emphasized that the age at diagnosis
was lower for mutated patients than wild-type ones: this fact
suggests that biomolecular changes in RET can induce a more
aggressive disease [24]. Correspondingly, higher PTTG1
expression in MTC patients was associated with advanced
stage of disease (stages III and IV) with extracapsular exten-
sion (T3 and T4), with lymph node metastases (N1) and per-
sistence of disease, suggesting a potential prognostic value for
PTTG1 in sporadic MTC. The role of PTTG1 protein is two
sided: on one hand it regulates the cell cycle and on the other
it is involved in tumorigenesis and therefore prooncogenic.
In the latter case it has been demonstrated an overexpression
(or a non-degradation thereof) in diﬀerent tumor types [25,
26]. However, the precise role of PTTG1 is not completely
elucidated: it is probably cell line dependent and it is impli-
cated in the physiological regulation of the cell cycle even in
tumor cells [25]. Nonetheless, a possible implication of
PTTG1 in the angiogenic process and in tumor progression
has been noted in a follicular thyroid carcinoma model, such
as a transgenic TRβPV mouse which spontaneously devel-
oped this tumor with distant metastases. The deletion of
the pttg1 gene in the transgenic mouse (TRβPV/PV pttg1-/-)
decreased vascular invasion accompanied by a decrease in
FGFR1, FGF-2, and VEGF and decreased tumor mass,
although it did not prevent tumor initiation [27]. Whether
this can be considered true even in MTC needs to be demon-
strated; however, tyrosine kinase inhibitors such as vandeta-
nib and cabozantinib eﬀectively act on VEGFR2 and
therefore on VEGF-mediated angiogenesis. It is notable that
only the work of Zatelli et al. showed an overexpression of
PTTG1 (evaluated by Northern blot) in 19 MTC patients
(3 nonsporadic cases) [26]. The authors suggested that this
overexpression could be potentially associated with tumor
progression, but given the small number of samples, they
turned to the cell model to positively substantiate their
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results. Our results corroborate and reinforce these data,
given the wide casuistry analyzed.
Similarly, the expression of AURKA in MTC patients was
evaluated by a unique work [14]. Baldini and collaborators
evaluated AURKA in 26 cases of MTC and found no signiﬁ-
cant correlation with tumor stage (comparable to our data),
but we also reported a signiﬁcant diﬀerence between AURKA
expression levels in MTC when compared to the normal thy-
roid. This diﬀerence could be imputable to the number of
samples analyzed, which in our casuistry was larger. Further-
more, AKA is involved in tumorigenesis, being overex-
pressed in numerous cancer types [22, 28]. Diﬀerently from
PTTG1, the AKA role in tumor transformation is better
known. The upregulation of AKA (but also of Aurora kinase
B) induces defects in chromosomal segregation and conse-
quently aneuploidy, which inevitably leads to malignant
transformation [29]. In addition, we found an interesting
correlation between AURKA and PTTG1, which relates them
to a fundamental function of cell processes: cell cycle control.
The 2 factors seem to be associated: a work of Tong et al.
demonstrated with a protein array screening that AKA and
PTTG1 could be coimmunoprecipitated suggesting an inter-
action and colocalization of the 2 factors in a cell model of
colorectal cancer [30]. The authors also suggested, again by
direct demonstration with the in vitromodel, that the knock-
down of PTTG1 might be a potential approach to improve
the eﬃcacy of Aurora kinase inhibitors, drugs not yet
approved for cancer treatment, although many clinical trials
have been completed or are still ongoing in order to evaluate
their use in antitumor therapy.
It is already known that the Ki-67 value is correlated with
the mutational status of RET and this ﬁnding could be useful
for the risk stratiﬁcation of sporadic MTC patients. More-
over, Ki-67 is associated with the presence of metastatic
lymph nodes, the presence of metastases, and the persistence
of disease [5]. We also observed a correlation between Ki-67
levels and PTTG1 expression. In the literature, there are only
2 observational works that explored this association. One
work showed the signiﬁcant association between PTTG1
and Ki-67 in pituitary adenomas [31], while the other stud-
ied the combination of Ki-67, Galectin-3, and PTTG to dis-
tinguish malignant forms of papillary or follicular thyroid
cancer [21]. Our ﬁnding is therefore the ﬁrst to associate
Ki-67 levels with PTTG1 expression in sporadic MTC. We
can speculate that these 2 factors can play a substantial
role in tumor cell processes: while PTTG1 is involved in
the cell cycle, Ki-67 is a marker of active cell proliferation,
altered in numerous neoplasms and associated with the
prognosis [32]. However, the statistical association does
not imply a causal relationship, and indeed, there are no
works that can demonstrate a direct interaction of PTTG1
and Ki-67 from a biomolecular point of view, unlike for
PTTG1 and AURKA.
Furthermore, the presence of stromal desmoplasia was
investigated in MTC samples by paraﬃn-embedded tissue
sections. We showed a strong correlation of stromal desmo-
plasia with lymph node metastasis (p < 0 001) (Figure S2A).
This result is in agreement with previous ﬁndings [23]
and conﬁrms the prognostic potential of this data, as also
suggested by PTTG1 expression, which is strictly associated
(p = 0 01) with stromal desmoplasia (Figure S2B).
In conclusion, in sporadic MTC, the presence of an
altered expression of PTTG1 and AURKA is a negative prog-
nostic factor associated with a more aggressive course of dis-
ease (advanced stage and disease persistence). However, the
presence of progressive disease and the risk of death also
depend on other molecular mechanisms acting on neoplastic
proliferation, of which the expression of Ki-67 is a possible
index. In addition to PIK3/Akt and MAPK pathways acti-
vated by RET, it is possible that PTTG1 and AKA could be
implicated in further intracellular signaling pathways not
yet suﬃciently investigated, in particular those related to
the cell cycle process. More work is needed to elucidate
this hypothesis.
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Supplementary Materials
Figure S1: PTTG1 expression levels by qRT-PCR analysis. (a)
Relationship between PTTG1 levels and the stage. (b) Rela-
tionship between PTTG1 levels and the value of T. (c) Rela-
tionship between PTTG1 levels and the presence (N+) or
absence (N-) of regional lymph node metastasis. (d) Rela-
tionship between PTTG1 levels and remitted or persistent
disease. Each circle represents an individual sample; each
bar represents the mean value of PTTG1; vertical lines repre-
sent 95% CI. Figure S2: stromal desmoplasia statistical
analysis. (a) Association between stromal desmoplasia and
lymph node metastasis (Fisher’s exact test): n = 0, no lymph
node metastasis; n = 1, lymph node metastasis. (b) Associa-
tion between stromal desmoplasia and mean PTTG1 expres-
sion by box plot representation (independent sample t-test).
(Supplementary Materials)
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